Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model

Experimental design and study overview. a Study design: genes expressing intrabodies or saline vehicle were delivered by viral vector into animals previously lesioned with an α-syn overexpression vector for observation of treatment effects on behavior and post-mortem analysis of pathology. b Model overview of α-syn overexpression via viral vector delivery of human α-syn into the substantia nigra pars compacta (scale bar: B—50μm). c Schematic of α-syn protein and target regions for nanobody aptamers VH14*PEST and NbSyn87*PEST. d Diagram of the process of α-syn fibril formation, sites of intrabody binding, and intrabody-mediated protein clearance mechanism